- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 26, Issue 10, 2020
Current Pharmaceutical Design - Volume 26, Issue 10, 2020
Volume 26, Issue 10, 2020
-
-
Epidemiology of Non-alcoholic Fatty Liver Disease in North America
Authors: Tamoore Arshad, Pegah Golabi, Linda Henry and Zobair M. YounossiNonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease worldwide. This is primarily driven by the global epidemic of obesity and diabetes as well as the aging of the general population. Most of the epidemiology data of NAFLD for North America are published from studies originating in the United States (U.S.). The overall prevalence of NAFLD in the U.S. is estimated to be Read More
-
-
-
Genetics and Epigenetics in the Clinic: Precision Medicine in the Management of Fatty Liver Disease
Authors: Annalisa Cespiati, Neil A. Youngson, Aikaterini Tourna and Luca ValentiThis narrative review will discuss the current evidence supporting the possible application of precision or personalized medicine to the management of nonalcoholic or “metabolic” fatty liver disease (NAFLD), based on recent progress in the understanding of the genetics and epigenetics of the disease. The prevalence of NAFLD, which can progress to cirrhosis and hepatocellular carcinoma, is constantly increasing worldwide. Ac Read More
-
-
-
Combined use of Genetic Polymorphisms and Elastographic Techniques in NAFLD: Fact or Fiction?
Authors: Rosa Lombardi, Silvia Fargion and Anna L. FracanzaniNon-alcoholic fatty liver disease (NAFLD) includes liver diseases ranging from simple steatosis to progressive forms characterized by high rates of complications and mortality, namely fibrosis, cirrhosis and hepatocellular carcinoma. Identification of patients with simple steatosis who will evolve to a more severe liver disease would allow better management of risk factors. Liver biopsy is the gold standard for the staging of NAFLD Read More
-
-
-
Dysmetabolic Iron Overload in Metabolic Syndrome
Background: We sought to determine the association of dysmetabolic iron overload syndrome (DIOS) with metabolic syndrome (MetS). Methods: Several studies have shown that DIOS is associated with Mets, mainly through the pathogenesis of its components: type 2 diabetes mellitus (T2DM), essential hypertension, non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (POS). Results: Serum ferritin levels incr Read More
-
-
-
Dysmetabolic Hyperferritinemia and Dysmetabolic Iron Overload Syndrome (DIOS): Two Related Conditions or Different Entities?
Authors: Raffaela Rametta, Anna L. Fracanzani, Silvia Fargion and Paola DongiovanniHyperferritinemia is observed in one-third of patients with non-alcoholic fatty liver disease (NAFLD) and Metabolic Syndrome (MetS). The condition characterized by increased body iron stores associated with components of MetS has been defined as Dysmetabolic Iron Overload Syndrome (DIOS). DIOS represents the most frequent iron overload condition, since it is observed in 15% of patients with MetS and in half of those Read More
-
-
-
Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?
Authors: Margaret Spinosa and Jonathan G. StineNonalcoholic fatty liver disease is the leading cause of liver disease worldwide. It has expansive extrahepatic morbidity and mortality including increased rates of both cardiovascular disease and venous thromboembolism. Derangements in primary, secondary and tertiary hemostasis are found in nonalcoholic fatty liver disease independent of those ascribed to end-stage liver disease. The abnormalities across all stages of Read More
-
-
-
Risk of Kidney Dysfunction IN Nafld
Authors: Alessandro Mantovani, Chiara Zusi, Andrea Dalbeni, Giorgio Grani and Elena BuzzettiBackground: The timely identification of traditional and non-traditional precursors and risk factors for chronic kidney disease (CKD) (a common systemic disease defined as a decreased kidney function documented by reduced glomerular filtration rate, or markers of kidney damage, or both) is relevant in clinical practice, as CKD increases the risk of end-stage renal disease and other serious comorbidities. A possible relationsh Read More
-
-
-
Modifiers of Liver-Related Manifestation in the Course of NAFLD
Authors: Patrik Nasr, Julia Blomdahl, Stergios Kechagias and Mattias EkstedtNon-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease affecting approximately 25% of the global population. There is a strong association between the severity of NAFLD and the components of the metabolic syndrome. NAFLD is also independently associated with cardiovascular disease and type 2 diabetes mellitus (T2DM). The progressive potential of non-alcoholic fatty liver diseas Read More
-
-
-
Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD)
Authors: Michael P. Johnston, Janisha Patel and Christopher D. ByrneNon-alcoholic fatty liver disease (NAFLD) and alcohol related fatty liver disease (AFLD) both represent a spectrum of liver disease severity from hepatic steatosis to fibrosis and cirrhosis. Both NAFLD and AFLD are common diseases in the general population. NAFLD affects ~25% of the adult global population whilst AFLD has become the commonest indication for liver transplantation in the United States. It is often not possible Read More
-
-
-
Nonalcoholic Fatty Liver Disease versus Alcohol-related Liver Disease: Is it Really so Different?
Authors: Ana Craciun, Caroline Lackner and Helena Cortez-PintoNonalcoholic fatty liver disease and alcohol-related liver disease together, compose the majority of cases of liver disease and cirrhosis worldwide. Although in the last years, there has been much interest in the differentiation between the two entities, it is increasingly recognized that a large overlap exists between them. The main pathophysiological aspects are very similar, with the exceptions of mechanisms directly related Read More
-
-
-
Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update
Background: Lifestyle interventions aimed at weight loss have been associated with improved liver enzymes, reduced intrahepatic triglyceride content, and improved histology (including reduced fibrosis stage). Objective: To revise the evidence on the beneficial effects of lifestyle changes accumulated since 2015, following the publication of the pivotal Cuban experience with histologic outcome. Methods: A PubMed search Read More
-
-
-
NAFLD at the Interface of the Mother-Infant Dyad
Authors: Sara Bertrando and Pietro VajroThis review aims to focus the links existing between several aspects of the mother-child dyad in the intricate playground of obesity and Metabolic Syndrome (MetS), including its hepatic component, the Non- Alcoholic Fatty Liver Disease (NAFLD). In recent years human and animal model studies have shown that dietary interventions in mothers and offspring can be successful in reducing the risk of NAFLD development. Evi Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
- Issue 46
- Issue 45
- Issue 44
- Issue 43
- Issue 42
- Issue 41
- Issue 40
- Issue 39
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
